XtalPi Holdings Limited (2228) Fair Value & Analysis
Healthcare · HK · Market cap HK$32.9B (≈ $4.2B) · ISIN KYG7S12M1051
What is XtalPi Holdings Limited really worth?
Below-average quality, and trading another 729% above our fair value of HK$0.8840.
Strengths
Risks
Fair value as of: Aug 13, 2026
From 12 valuation models · updated 22 days ago
Share price +0.1% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (HK$0.9265). The favourable scenario is already priced in.
- Weak quality (38/100) and above fair value at the same time, the margin of safety is missing on both counts.
- The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Price vs Fair Value (2 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
27‑month range HK$3.26 – HK$15.60 · fair‑value band HK$0.6205 – HK$0.9265 · the HK$7.33 price screens above the HK$0.8840 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
XtalPi Holdings Limited (2228) currently trades at HK$7.33, while our model-based Fair Value estimate is HK$0.8840, implying the stock looks roughly 729.2% overvalued today. The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of HK$2.00 per share, and 0 of the 12 models we run sit above the HK$7.33 price. Bear case: the Dividend Discount group reads lowest at HK$0.2400, and 12 of the 12 models stay below the price. Evidence for this calculation is low.
Over the trailing twelve months, XtalPi Holdings Limited generated revenue of HK$803M at a net margin of 15.4%. Revenue grew 74.3% year over year. It earns a return on equity of 2.0%. The balance sheet holds a net cash position of HK$2.1B. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$0.6205 (bear case) to HK$0.9265 (bull case); at HK$7.33, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 52% below its 52-week high and 39% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −64% fair-value upside, at −88%, 2228 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$0.0136 per share, which is 1.5 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 12 models by family
Widest divergence: DCF Models (HK$2.00) versus Dividend Discount (HK$0.2400). Highest evidence: Residual Income (76).
Notify me when 2228 reaches fair value
Put 2228 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 41 · Market factors (momentum, volatility) 17
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
XtalPi Holdings Limited operates as a research platform company in Mainland China, the United States, and internationally.
Full company description
XtalPi Holdings Limited operates as a research platform company in Mainland China, the United States, and internationally. The company offers XmartChem, an intelligent synthesis workstation which automates the chemical synthesis process; ChemPlus, desktop solid dispensing device; PatSight, an optical chemical structure extraction tool for patents; and XFEP, a software for rapid FEP calculations using cloud computing. It also provides XMolGen, a generative chemistry tool; and drug discovery solutions, such as hit discovery, hit or lead optimization, and biology capabilities, as well as PepiX, which generates stable peptides. In addition, the company offers discovery chemistry solutions, including automation-aided chemical synthesis and focused library; and XtalGazer, a solid-state research solution. It has a strategic collaboration with Pfizer to co-build an AI-driven molecular simulation research and development platform; DoveTree to develop therapeutics designed for multiple difficult-to-drug targets; and strategic partnership with an international biopharmaceutical company to develop oral small molecule therapeutics for a GPCR target. The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
XtalPi Holdings Limited reported revenue of 782M CNY in FY2025 versus 62.8M CNY in FY2021, a compound +87.8%/yr. Reported net income was 121M CNY in FY2025.
2228 screens 729% overvalued. Compare with Veeva Systems Inc →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- XtalPi Holdings Announces 2026 Interim Results
- XtalPi Holdings Limited to Announce 2026 Interim Results on August 19, 2026
- XtalPi Holdings (SEHK:2228) Stock Valuation Check After Recent Weak Momentum
- XtalPi Announces Strategic Partnership with a Leading Biopharma to Develop Oral Small Molecule Therapeutics for a GPCR Target
Peer Group
Health Information Services · 128 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Health Information Services median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $282.13 | $91.49 | −68% |
| Pro Medicus Limited PME | A$183.71 | A$23.74 | −87% |
| BrightSpring Health Services, Inc BTSG | $59.68 | $21.31 | −64% |
| HealthEquity, Inc HQY | $104.27 | $56.63 | −46% |
| Hinge Health, Inc HNGE | $86.32 | $24.03 | −72% |
| 10x Genomics, Inc TXG | $55.63 | $17.18 | −69% |
| Waystar Holding WAY | $25.76 | $12.86 | −50% |
| Doximity, Inc DOCS | $24.74 | $25.91 | +5% |
| Privia Health Group PRVA | $21.07 | $5.26 | −75% |
| IKS IKS | ₹1,785 | ₹830.74 | −53% |
Compare XtalPi Holdings Limited with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is XtalPi Holdings Limited (2228) overvalued or undervalued?
What is the fair value of 2228?
What is the quality score of 2228?
What is the revenue of XtalPi Holdings Limited (2228)?
What is the net profit margin of 2228?
Does XtalPi Holdings Limited pay a dividend?
Watch XtalPi Holdings Limited in the live analysis
One click puts XtalPi Holdings Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.